MARKET

KURA

KURA

Kura Oncology Inc
NASDAQ
11.39
-0.18
-1.56%
After Hours: 11.44 +0.05 +0.44% 19:40 09/11 EDT
OPEN
11.58
PREV CLOSE
11.57
HIGH
11.75
LOW
11.34
VOLUME
2.12M
TURNOVER
--
52 WEEK HIGH
13.90
52 WEEK LOW
7.36
MARKET CAP
1.01B
P/E (TTM)
-3.3878
1D
5D
1M
3M
1Y
5Y
1D
Kura Oncology (KURA) Receives a Buy from Leerink Partners
TipRanks · 3d ago
Kura Oncology (KURA) Could Be 61% Below Fair Value After Caspian Therapeutics Deal
Simply Wall St · 3d ago
Kura Oncology (KURA) Receives a Buy from Barclays
TipRanks · 3d ago
Wainwright says Caspian spinout lets Kura refocus on oncology, keeping 50% stake
TipRanks · 4d ago
Kura Oncology Pivots Diabetes Strategy Into $50 Million Subsidiary
Benzinga · 4d ago
Kura Oncology Establishes Caspian Partnership for Cardiometabolic Focus
TipRanks · 4d ago
Kura Oncology launches Caspian Therapeutics
TipRanks · 4d ago
Kura Oncology appoints Jennifer Fulk as CFO
Seeking Alpha · 5d ago
More
About KURA
Kura Oncology, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on precision medicine for the treatment of cancer. Its pipeline consists of small molecule product candidates that target cancer signaling pathways. Its product candidates include KOMZIFTI (Ziftomenib), Tipifarnib, and Darlifarnib (KO-2806). Ziftomenib, is a potent, selective, reversible and oral small molecule inhibitor that blocks the interaction of two proteins, menin and the protein expressed by the Lysine K-specific Methyl Transferase 2A gene, or KMT2A gene. Ziftomenib is a selective investigational inhibitor of the menin-KMT2A protein-protein interaction for the treatment of genetically defined subsets of acute leukemias. Tipifarnib is a potent, selective and orally bioavailable farnesyl transferase inhibitor (FTI). The KO-2806 is an FTI, is being evaluated in a Phase I first-in-human trial as a monotherapy and in combination with other targeted therapies.

Webull offers Kura Oncology Inc stock information, including NASDAQ: KURA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, KURA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading KURA stock methods without spending real money on the virtual paper trading platform.